Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003715 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Phase 2 study, sponsored by AVAX Technologies.
- Terminated
- Registry status
- Phase 2
- Development phase
- 425
- Enrollment target
NCT00003715: Clinical Trial Phase 2 study, sponsored by AVAX Technologies.
NCT00003715 is a Phase 2 study that was terminated before completion, run by AVAX Technologies. The registered enrollment target is 425 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (220% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003715, a Phase 2 study, was terminated before completion, sponsored by AVAX Technologies.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 425 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Interventions
- DRUG cyclophosphamide
- DRUG chemotherapy
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL BCG vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 1998-12 |
| Phase | Phase 2 |
Why NCT00003715 stopped before completion
NCT00003715 is an interventional study that assigns participants to a tested intervention. The registered 425 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (220% higher).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003715 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003715 about?
NCT00003715 is a clinical study titled "Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma". RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alf...
What is the current status of trial NCT00003715?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 425 participants. The study started on 1998-12.
What interventions are being tested in trial NCT00003715?
The interventions under investigation include: cyclophosphamide (DRUG), chemotherapy (DRUG), recombinant interferon alfa (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), BCG vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003715?
This trial is sponsored by AVAX Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003715's enrollment target sits among peer trials
425 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
- NCT05340738 · 425 participants · NA
AI-Based Fidelity Feedback to Enhance CBT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia